DDMAC's "Bad Ad" Enforcement Often Requires Affidavits
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Division of Drug Marketing, Advertising and Communications is preparing several enforcement letters triggered by complaints from doctors.
You may also be interested in...
"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One
In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.
"Bad Ad" Program Set To Expand After Opening Spigot Of Complaints In Year One
In its first year of operation, FDA's "Bad Ad" program succeeded in more than tripling the number of complaints the agency receives about deceptive drug advertising, and now the agency is assessing how best to expand upon the success of the initiative.
Could Forest's DDMAC Letter For Off-Label Promotion Doom CEO Solomon?
A physician complained to FDA's "Bad Ad" program about a Forest Laboratories sales representative's off-label claims for the fibromyalgia drug Savella.